Table 1 The resectable pancreatic cancer clinical trial with S0(tc=1)=35%, and S1(tc=1)=50% to attain 90% power at the significance level of 10%
From: Two-stage optimal designs with survival endpoint when the follow-up time is restricted
Survival endpoint | Simon’s design, interim accrual | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The proposed method | Belin | No | Yes | ||||||||||
n 1 | n | c 1 | c | E S S 0 | E T S L 0 | E S S 0 | n | E S S 0 | E T S L 0 | n | E S S 0 | E T S L 0 | |
Minimax | 44 | 73 | 0.240 | -1.281 | 61.3 | 3.1 | 59.3 | 4.0 | 72 | 69.8 | 3.5 | ||
Optimal | 41 | 79 | -0.085 | -1.279 | 58.7 | 2.9 | 59.1 | 69 | 53.2 | 3.6 | 81 | 67.4 | 3.2 |